These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11446520)

  • 1. The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
    Press RA
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):100S-104S. PubMed ID: 11446520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.
    Moran GJ
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):95S-99S. PubMed ID: 11446525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: focus on gatifloxacin.
    Pelly L
    Adv Ther; 2002; 19(5):229-42. PubMed ID: 12539883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy.
    Ramirez JA
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):79S-82S. PubMed ID: 11446522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparfloxacin: a review.
    Schentag JJ
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents?
    Vogel F
    Drugs; 2002; 62(2):309-17. PubMed ID: 11817975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC; Davis CW
    Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin and moxifloxacin: two new fluoroquinolones.
    Med Lett Drugs Ther; 2000 Feb; 42(1072):15-7. PubMed ID: 10705891
    [No Abstract]   [Full Text] [Related]  

  • 12. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
    Feagan BG
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
    Milkovich G
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):83S-88S. PubMed ID: 11446523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The proper use of quinolones to the elderly patient with community-acquired pneumonia examined by Monte Carlo simulation].
    Yanagihara K; Morinaga Y; Fukushima K; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Miyazaki Y; Hirakata Y; Tashiro T; Kohno S
    Jpn J Antibiot; 2007 Oct; 60(5):251-6. PubMed ID: 18198653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
    Hoeffken G; Meyer HP; Winter J; Verhoef L;
    Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin: a review of its use in the management of bacterial infections.
    Keating GM; Scott LJ
    Drugs; 2004; 64(20):2347-77. PubMed ID: 15456331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.